FDA again rejects Orexo's nasal spray for opioid overdose rescue
For a second time, the FDA has turned away Orexo’s nasal spray treatment for opioid overdoses.
The company will need to complete another “human factor” …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
